The present invention belongs to the field of
genetic engineering technology, and specifically relates to a miRNA in
skeletal muscle exosomes and its application. The inventors continued to study the exosomes of hypoxic
skeletal muscle cells on the basis of previous studies confirming that hypoxic
skeletal muscle cells promote endothelial
cell proliferation and participate in
angiogenesis by secreting exosomes. Through further in-depth research on exosomes, a new miRNA-like molecule with significant
differential expression was found by
RNA sequencing, named novel-196.
Skeletal muscle cells significantly reduced the expression of novel_196 under hypoxia. The authenticity of novel_196 was further verified and functionally characterized, and it was found that novel_196 was closely related to
angiogenesis. Using
bioinformatics software analysis, it was predicted that the
target gene bound to novel_196 was FGF2. Experiments confirmed that reducing novel_196 expression can reduce the inhibition of transcription and translation of the
target gene FGF2, thereby promoting the proliferation, migration and
tube formation of endothelial cells and promoting
angiogenesis. It can be seen that novel_196 is of great significance to the response of skeletal
muscle to ischemic state.